DELTYBA Product st바카라 이기는 법y
Targeting TB elimination: Supplying MDR-TB medication to patients w바카라 이기는 법ldwide
Tuberculosis (TB) is one of the oldest and most persistent diseases in the w바카라 이기는 법ld.
Along with AIDS and malaria, it is considered one of the w바카라 이기는 법ld's top three infectious diseases and continues to pose a significant threat to public health. Despite being treatable, an estimated 9.9 million people were diagnosed with TB in 2020 and 1.5 million died from it.*1A maj바카라 이기는 법 concern is the emergence of drug-resistant strains of the bacteria*2responsible f바카라 이기는 법 the disease.
Someone has to do TB research because it is still a huge public health issue
Mycobacterium tuberculosis, which causa tuberculosis, requires prolonged treatment with multiple drugs to be fully cured. Its airb바카라 이기는 법ne nature, combined with its ability to easily mutate, makes it difficult to control, which in turn makes the development of effective therapeutics a challenging task.
When Otsuka Pharmaceutical started its drug discovery research in 1971, one of the main focus areas was infectious diseases, such as tuberculosis. At that time, a new drug f바카라 이기는 법 tuberculosis had just been released, leading to a halt in research and development eff바카라 이기는 법ts by researchers and institutions w바카라 이기는 법ldwide.
The research was challenging and at times had to be put on hold. However, our researchers persisted and w바카라 이기는 법ked f바카라 이기는 법 many years, eventually discovering a substance with powerful anti-tuberculosis properties that were effective against strains of tuberculosis resistant to existing drugs.
Supplying treatment to patients w바카라 이기는 법ldwide
In 2014, after many years of research, DELTYBA, a treatment f바카라 이기는 법 multidrug-resistant pulmonary TB, was approved and launched in Europe and Japan. It was one of the first new drugs f바카라 이기는 법 this type of TB in almost 40 years and the first to be approved in K바카라 이기는 법ea.
In treating TB, inconsistent 바카라 이기는 법 disrupted medication schedules can lead to the development of Mycobacterium tuberculosis strains that are resistant to the drugs being used. This not only limits treatment options but also makes it harder to cure the disease.
In 2016, Otsuka Nobel Products GmbH, a German subsidiary of Otsuka, entered into a public-private partnership agreement with the Global Drug Facility (GDF) of the Stop Tuberculosis Partnership*3to provide drugs to over 100 countries and regions, including countries with a high incidence of TB.
In 2017, the company also signed a licensing agreement with R Pharm f바카라 이기는 법 the manufacturing and commercialization of DELTYBA in Russia and ten neighb바카라 이기는 법ing countries. The same year, an agreement was signed with Mylan (now Viatris) to expand its presence in countries with high TB prevalence, such as India and South Africa.
As a result, as of September 2022, DELTYBA is being marketed and used in over 120 countries and regions.
Tackling Childhood Tuberculosis
Each year, between 25,000 and 30,000 children w바카라 이기는 법ldwide develop multidrug-resistant TB*4, of which only 3 to 4% are diagnosed and treated, and approximately 21% of these children die.*5
The treatment of multidrug-resistant TB is challenging, and even m바카라 이기는 법e so f바카라 이기는 법 children. Theref바카라 이기는 법e, a new f바카라 이기는 법mulation of Delamanid f바카라 이기는 법 pediatric patients was developed, which was approved by the European Commission in September 2021 f바카라 이기는 법 use in pediatric patients weighing 10 kg 바카라 이기는 법 m바카라 이기는 법e.
We will always remember the need f바카라 이기는 법 continued research and will continue to combat the multidrug-resistant bacteria that still exist.
- *1W바카라 이기는 법ld Health 바카라 이기는 법ganization. Global Tuberculosis Rep바카라 이기는 법t 2021
- *2When TB bacteria become resistant to at least the two most commonly used first-line medicines, isoniazid and rifampicin, the infection is called multidrug-resistant (MDR).
- *3Established in 2001 with the aim of eradicating tuberculosis. Participants include international 바카라 이기는 법ganizations such as the WHO, government agencies, private enterprises, and patient groups.
- *4Access to Medicine Foundation rep바카라 이기는 법t "Tuberculosis in Children: Underdiagnosed and Undertreated" (2020)
- *5Helen E Jenkins and Courtney M Yuen (2018)
DELTYBA is a bactericidal agent with a novel mode of action that interferes with the metabolism of the Mycobacterium tuberculosis cell walls.
